AOD-9604

AOD-9604 is a synthetic peptide fragment corresponding to a portion of the C-terminal region of human growth hormone. It has been promoted in some experimental and commercial settings for potential roles in fat metabolism and weight-related endpoints.

Regulatory positions and claims about AOD-9604 vary widely by region and product type. Many uses described in marketing materials are more expansive than what is supported by formal, high-quality clinical evidence.

Proposed mechanisms for AOD-9604 are based largely on preclinical work and focus on potential effects on lipid metabolism and adipose tissue. High-level themes include:

• Acting on pathways involved in fat breakdown and energy expenditure

• Attempting to separate certain metabolic effects of growth hormone from its broader endocrine footprint

How these mechanistic findings translate into meaningful, clinically relevant outcomes in humans is an area of ongoing debate and research.

In many jurisdictions, AOD-9604 is not an approved medicine for weight management or metabolic disease. It may appear in experimental protocols or in wellness-oriented products marketed around fat loss.

Because regulatory status, product quality, and evidence strength vary, any consideration of AOD-9604 should be grounded in local regulations and a clear understanding of the difference between exploratory research and established obesity or metabolic treatments.

AOD-9604 is now named individually on the WADA Prohibited List, under the growth hormone sub-section S2.2.3 rather than the S0 catch-all it was once assigned to. That move matters, because the ambiguity in the earlier classification is the whole reason AOD-9604 became one of the most litigated peptides in sport.

The Essendon saga, accurately. During the Essendon Football Club's 2012 supplements program, players were injected with AOD-9604. At the time the compound was not written on the Prohibited List by name, and the club argued it had been cleared. On 22 April 2013 WADA published a statement that AOD-9604 was still in pre-clinical and clinical development, had not been approved for therapeutic use by any government health authority anywhere, and therefore fell under S0. Australia's anti-doping authority, then ASADA, rejected the idea that it had ever said otherwise — CEO Aurora Andruska wrote to the AFL that "at no point has it advised any party that AOD-9604 was permitted in sport, and our advice to the sporting community has always been consistent with WADA" (AFL.com.au).

The eventual anti-doping rule violations against the 34 Essendon players were nevertheless brought on thymosin beta-4, not AOD-9604, and it was those charges that the Court of Arbitration for Sport upheld in January 2016 with two-year bans. AOD-9604 is often described as "the Essendon drug"; the sanctions were not for it. See TB-500 for that case.

Detection. A urine screening method for AOD-9604 has been published with a limit of detection of 50 pg/mL, and the same work identified a metabolite (CRSVEGSCG) "significantly more stable than the other metabolites or the parent compound," which the authors proposed as a way to extend the detection window (Cox et al., Drug Test Anal 2015). The compound is not a testing blind spot.

Reported experiences include local injection-site reactions and nonspecific symptoms such as headache, fatigue, or GI upset. Robust, long-term safety data across diverse populations are relatively sparse.

As with other experimental peptides, careful attention to product sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation.

AOD-9604 is a fragment of HGH (Tyr-hGH177-191) believed to influence lipid metabolism without the insulin-desensitizing effects of full HGH.

This information summarizes commonly discussed research practices and does not constitute medical advice.

AOD-9604 is supplied as a lyophilized powder for reconstitution and subcutaneous injection, though the original animal research dosed it orally. Beyond the obesity work, it has been studied in combination with hyaluronic acid as an intra-articular injection in a rabbit osteoarthritis model — a preclinical pairing, not an available therapy.

Research on AOD-9604 has examined its effects on fat metabolism and related markers in preclinical models and limited human studies. Results have generated interest but also raised questions about effect size, study design, and reproducibility.

Because the evidence base is evolving and sometimes mixed, claims about AOD-9604 should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this peptide, see:

• AOD-9604 benefits and areas of interest
• AOD-9604 side effects and safety context
• AOD-9604 dosing concepts (educational)
• AOD-9604 research and evidence overview

Does AOD-9604 work for fat loss? In rodents, yes — it increased fat breakdown and halved weight gain in obese rats. In humans, no: the developer's obesity trials failed to show meaningful weight loss, the program was abandoned, and no positive human efficacy study was ever published.

Does AOD-9604 raise growth hormone or IGF-1? No. It is a fragment of GH itself, not a secretagogue — it does not trigger GH release, and it is not reported to raise IGF-1 or promote tissue growth. That subtraction was the entire design rationale.

Is AOD-9604 FDA-approved? No. It reached mid-stage clinical trials for obesity in the early 2000s and development stopped when efficacy was not demonstrated. It is sold today only as an unregulated research chemical.

Why is it banned in sport if it doesn't work? WADA prohibits it under S0, the category for substances without approval for human use — the ban follows from its unapproved status, not from proven performance-enhancement. Anti-doping labs can detect it in urine.

Is anyone still researching it? The most recent peer-reviewed work is preclinical joint research: combined with hyaluronic acid, it reduced cartilage damage in a rabbit osteoarthritis model. No human trials in any indication are published.